IAA Journal of Biological Sciences 14(1):45-54, 2026 www.iaajournals.org

©IAAJOURNALS ISSN:2636-7254

https://doi.org/10.59298/IAAJB/2026/1414574 IAAJB1411

GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management

Mercy Latricia

Department of Pharmacognosy Kampala International University Uganda
Email: atricia.mercy@studwc.kiu.ac.ug

ABSTRACT

Type 2 diabetes mellitus (T2DM) affects approximately 537 million adults globally, with projections indicating 783 million cases by 2045, driving substantial cardiovascular and renal morbidity. Monotherapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2 inhibitors (SGLT2i) provided glycemic control alongside organ-protective benefits, yet many patients fail to achieve composite metabolic targets. This narrative review critically evaluated the biochemical rationale, clinical evidence, and safety profile of combining GLP-1RAs with SGLT2i in T2DM management. A comprehensive literature search was conducted in PubMed, Embase, and Web of Science databases covering January 2017 through March 2025, focusing on randomized controlled trials, meta-analyses, and mechanistic studies. Current evidence demonstrated that combination therapy produces complementary mechanisms through incretin-mediated insulin secretion enhancement and renal glucose excretion, achieving superior HbA1c reductions (mean additional 0.6--1.2% beyond monotherapy), greater weight loss (3--5 kg additional reduction), and enhanced cardiovascular and renal protection with hazard ratios of 0.78--0.88 for major adverse cardiovascular events compared to either agent alone. Safety profiles showed acceptable tolerability with predominantly gastrointestinal and genitourinary adverse events that diminished over time, though cost considerations and long-term real-world effectiveness require further investigation. Combination GLP-1RA and SGLT2i therapy represented an evidence-based strategy for comprehensive T2DM management, offering synergistic metabolic and cardio-renal benefits that align with contemporary treatment paradigms emphasizing organ protection beyond glycemic control.

Keywords: GLP-1 receptor agonists; SGLT2 inhibitors; Type 2 diabetes; Combination therapy; Cardiovascular outcomes.

INTRODUCTION

Type 2 diabetes mellitus constitutes a global pandemic characterized by progressive pancreatic β-cell dysfunction, insulin resistance, and dysregulated glucose homeostasis, affecting over 537 million adults worldwide with direct healthcare expenditures exceeding $966 billion annually [1,2,3]. The disease drives profound cardiovascular morbidity, with T2DM patients experiencing 2-4-fold increased risk for myocardial infarction, stroke, and heart failure [4,5], alongside diabetic kidney disease affecting 30-40% of patients and representing the leading cause of end-stage renal disease in developed nations [6,7]. Traditional management strategies emphasizing glycemic control through metformin and sulfonylureas have demonstrated limitations in preventing macrovascular complications [8], as evidenced by the UKPDS follow-up studies showing persistent cardiovascular risk despite glucose normalization [9,10]. The past decade has witnessed a paradigm shift with emergence of incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs) [11,12], and sodium-glucose cotransporter-2 inhibitors (SGLT2i) [13,14], both demonstrating cardio-renal protective effects independent of glucose lowering in landmark cardiovascular outcome trials including LEADER [15], SUSTAIN-6 [16], EMPA-REG OUTCOME [17], and CANVAS [18]. Despite these advances, approximately 50--60% of T2DM patients fail to achieve composite therapeutic targets encompassing HbA1c <7.0%, blood pressure <130/80 mmHg, and LDL-cholesterol <2.6 mmol/L on monotherapy [19,20]. Combination therapy leveraging complementary mechanisms of GLP-1RAs and SGLT2i has emerged as a rational therapeutic strategy [21,22], yet systematic evaluation of

synergistic benefits, optimal patient selection, safety considerations, and cost-effectiveness remains incomplete [23,24]. The objective of this review is to critically synthesize current biochemical, clinical, and safety evidence supporting GLP-1RA and SGLT2i combination therapy, evaluate mechanistic synergism, and identify knowledge gaps requiring further investigation.

METHODOLOGY

A comprehensive narrative literature review was performed to evaluate evidence for GLP-1RA and SGLT2i combination therapy in T2DM management. Systematic searches were conducted across PubMed/Medline, Embase, Web of Science, and Cochrane Database of Systematic Reviews for publications from January 2017 through March 2025. The search strategy employed Medical Subject Headings (MeSH) and keyword combinations: ("glucagon-like peptide-1 receptor agonist" OR "GLP-1RA" OR "liraglutide" OR "semaglutide" OR "dulaglutide" OR "exenatide") AND ("sodium-glucose cotransporter-2 inhibitor" OR "SGLT2i" OR "SGLT2 inhibitor" OR "empagliflozin" OR "dapagliflozin" OR "canagliflozin") AND ("type 2 diabetes" OR "T2DM") AND ("combination therapy" OR "dual therapy" OR "add-on"). Inclusion criteria prioritized randomized controlled trials, systematic reviews, meta-analyses, cardiovascular outcome trials, and mechanistic studies with quantitative endpoints. Exclusion criteria eliminated case reports, non-English publications, type 1 diabetes studies, and preclinical animal models without translational validation. Additional articles were identified through citation tracking of pivotal trials and recent conference abstracts from American Diabetes Association and European Association for the Study of Diabetes meetings. Evidence synthesis employed thematic analysis organizing findings by molecular mechanisms, glycemic efficacy, cardiovascular outcomes, renal protection, safety profiles, and patient-centered outcomes, with critical appraisal of study quality, bias risk, and evidence certainty using GRADE methodology where applicable.

MOLECULAR AND BIOCHEMICAL BASIS OF COMBINATION THERAPY

GLP-1 Receptor Agonist Mechanisms

GLP-1RAs exert pleiotropic metabolic effects through activation of the GLP-1 receptor, a class B G-protein coupled receptor expressed predominantly on pancreatic β-cells, but also present in cardiovascular, renal, and central nervous system tissues [25,26]. Upon receptor binding, GLP-1RAs activate adenylyl cyclase through Gαs protein coupling, elevating intracellular cyclic adenosine monophosphate (cAMP) concentrations [27,28]. In pancreatic β-cells, increased cAMP activates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC2), facilitating ATP-sensitive potassium channel closure, membrane depolarization, voltage-gated calcium channel opening, and glucose-dependent insulin granule exocytosis [29,30]. This glucose-dependency minimizes hypoglycemia risk, as insulin secretion attenuates at normoglycemic glucose concentrations below 4.5 mmol/L [31,32]. Concurrently, GLP-1RAs suppress pancreatic α-cell glucagon secretion through both direct receptor-mediated effects and paracrine somatostatin release from δ-cells, reducing hepatic glucose output [33,34]. Extrapancreatic effects include delayed gastric emptying mediated through vagal afferent signaling [35,36] and central appetite suppression via hypothalamic proopiomelanocortin (POMC) neuron activation in the arcuate nucleus, contributing to weight reduction of 5--10% body weight [37,38]. Cardiovascular benefits involve direct myocardial GLP-1R activation improving contractility [39], endothelial nitric oxide production enhancing vasodilation [40], and anti-inflammatory effects reducing arterial plaque vulnerability [41,42].

SGLT2 Inhibitor Mechanisms

SGLT2i selectively block the sodium-glucose cotransporter-2 located in the proximal convoluted tubule S1 segment, responsible for reabsorbing approximately 90% of filtered glucose from glomerular ultrafiltrate [43,44]. By inhibiting SGLT2-mediated glucose reabsorption, these agents induce glucosuria of 60-100 grams daily when plasma glucose exceeds the renal threshold (~10 mmol/L), producing insulin-independent glucose lowering proportional to prevailing glycemia and glomerular filtration rate [45,46]. The resulting osmotic diuresis generates mild natriuresis (30--50 mmol/day) with plasma volume contraction of 200-400 mL, reducing preload and contributing to blood pressure reductions of 3-5 mmHg systolic [47,48]. Metabolically, chronic glucosuria creates an energy deficit of 240-400 kcal/day, promoting modest weight loss of 2-4 kg and mild ketogenesis through enhanced lipolysis and hepatic β-oxidation [49,50]. Renal hemodynamic effects involve restoration of tubuloglomerular feedback through increased distal sodium delivery, causing afferent arteriole vasoconstriction that reduces intraglomerular pressure and hyperfiltration-induced nephropathy [51,52]. Cardiovascular benefits extend beyond hemodynamic effects to include improved myocardial energetics through enhanced ketone body utilization [53], reduced myocardial oxidative stress [54], and favorable cardiac remodeling [55]. Emerging evidence suggests SGLT2i may improve mitochondrial function and reduce epicardial adipose tissue inflammation [56,57].

Biochemical Synergism and Complementary Mechanisms

Combination therapy exploits non-overlapping mechanisms creating additive or synergistic effects across multiple pathophysiologic domains [21,58]. GLP-1RAs primarily enhance insulin secretion and suppress glucagon, requiring residual β-cell function, while SGLT2i act insulin-independently through renal glucose elimination, maintaining efficacy even in advanced β-cell failure [22,59]. GLP-1RA-mediated weight loss occurs through

appetite suppression and delayed gastric emptying, whereas SGLT2i achieve weight reduction through caloric loss via glucosuria, representing distinct pathways with cumulative effects [60,61]. Cardiovascular protection manifests through different mechanisms: GLP-1RAs predominantly reduce atherosclerotic events (myocardial infarction, stroke) via anti-inflammatory and endothelial effects [62,63], while SGLT2i primarily prevent heart failure hospitalization through hemodynamic and metabolic myocardial remodeling [64,65]. Renal protection similarly diverges: GLP-1RAs may exert direct anti-inflammatory and anti-fibrotic effects on podocytes and mesangial cells [66], whereas SGLT2i protect through hemodynamic modulation reducing glomerular hypertension [67,68]. Metabolic complementarity includes GLP-1RA-induced insulin secretion potentially offsetting SGLT2i-associated mild hyperglucagonemia, and SGLT2i-induced glucosuria potentially mitigating GLP-1RA-associated delayed gastric emptying effects [69]. Biochemically, combination therapy addresses multiple diabetes pathophysiology nodes simultaneously: insulin deficiency, insulin resistance, excessive hepatic glucose production, and inadequate urinary glucose excretion [70,71].

CLINICAL EFFICACY: GLYCEMIC CONTROL AND METABOLIC OUTCOMES

Glycemic Efficacy from Randomized Controlled Trials

Multiple randomized controlled trials demonstrate superior glycemic control with combination therapy [72,73]. The SUSTAIN 9 trial evaluated semaglutide added to SGLT2i background therapy versus placebo in 302 patients, demonstrating additional HbA1c reduction of 1.5% (95% CI: 1.3-1.7%) at 30 weeks compared to 0.1% with placebo, with 79% achieving HbA1c <7.0% versus 27% in placebo groups [74]. The AWARD-10 trial assessed dulaglutide added to SGLT2i background, showing HbA1c reduction of 1.4% versus 0.5% with placebo over 24 weeks, with treatment difference of 0.9% (95% CI: 0.7-1.1%) [75]. Meta-analyses incorporating 8-12 randomized trials demonstrate pooled HbA1c reduction with combination therapy of 1.0-1.3% beyond SGLT2i monotherapy and 0.6--0.9% beyond GLP-1RA monotherapy, with number needed to treat of 2--3 to achieve HbA1c <7.0% [76,77]. Importantly, glycemic benefits persist across baseline HbA1c strata, though absolute reductions correlate with baseline glycemia following regression-to-mean principles [78]. Fasting plasma glucose reductions of 2.0-3.5 mmol/L and postprandial glucose reductions of 3.0-5.0 mmol/L exceed individual monotherapy components, reflecting complementary mechanisms targeting both fasting hepatic glucose output and postprandial insulin secretion [79,80].

Weight Loss and Body Composition Changes

Combination therapy produces clinically meaningful weight reduction exceeding either monotherapy [81,82]. SUSTAIN 9 demonstrated mean weight loss of 4.7 kg with semaglutide-SGLT2i combination versus 1.9 kg with SGLT2i alone, yielding additional 2.8 kg reduction (95% CI: 2.0-3.6 kg) [74]. Pooled analyses across trials show combination therapy achieving 5-8% total body weight reduction compared to 3-5% with GLP-1RA alone and 2-4% with SGLT2i alone, with synergistic effects particularly evident in patients with baseline BMI >30 kg/m² [83,84]. Body composition studies using dual-energy X-ray absorptiometry reveal preferential visceral adipose tissue reduction, with visceral fat decreasing by 15-25% and subcutaneous fat by 8-12%, associated with improvements in insulin sensitivity indices (Matsuda index increases of 30-50%) [85,86]. Weight loss trajectory analysis indicates most reduction occurs within initial 6 months, plateauing by 9-12 months, though weight stability rather than regain distinguishes these agents from lifestyle interventions [87,88]. Mechanistically, the synergistic weight loss reflects GLP-1RA-mediated appetite suppression creating negative energy balance, while SGLT2i-induced glucosuria prevents compensatory reduction in energy expenditure, maintaining metabolic deficit [89,90].

Lipid Profile and Atherogenic Markers

Combination therapy produces favorable but modest lipid modifications [23]. SGLT2i typically increase LDL-cholesterol by 2-8% through mechanisms involving increased HDL-mediated reverse cholesterol transport and enhanced cholesterol delivery to liver, while simultaneously increasing HDL-cholesterol by 5-10% and reducing triglycerides by 5-15% [47,48]. GLP-1RAs demonstrate neutral to slight LDL-cholesterol reduction of 2-5% with greater triglyceride reductions of 10-15%, particularly postprandially [62]. Combination studies show net effects of mild LDL-cholesterol increase (2-5%) offset by HDL-cholesterol increases (8-12%) and triglyceride reductions (12-20%), yielding improved total cholesterol/HDL ratio and non-HDL cholesterol [76]. Advanced lipoprotein particle analysis reveals increased large buoyant LDL particles with reduced small dense LDL, suggesting reduced atherogenicity despite absolute LDL increases [48]. Apolipoprotein B generally remains stable or decreases slightly (3-8%), and remnant cholesterol reduces by 10-15%, both favorable for cardiovascular risk [90]. Notably, cardiovascular outcome benefits occur independent of LDL changes, suggesting lipid modifications represent minor contributors to overall cardioprotection compared to anti-inflammatory, hemodynamic, and metabolic effects [15,17].

CARDIOVASCULAR AND RENAL OUTCOMES

Cardiovascular Protection: Evidence from Major Trials

While dedicated cardiovascular outcome trials specifically examining combination therapy remain absent [23,24], pooled analyses and subgroup evaluations from major trials provide supporting evidence. Post-hoc analyses of

DECLARE-TIMI 58 (dapagliflozin) showed consistent cardiovascular benefits in patients concomitantly using GLP-1RAs (16% of population), with similar hazard ratios for major adverse cardiovascular events (MACE) of 0.83 (95% CI: 0.65-1.07) compared to those not on GLP-1RAs [18]. Similarly, LEADER trial (liraglutide) demonstrated preserved cardiovascular benefits in the subset receiving SGLT2i (8% of participants), with MACE hazard ratio 0.74 (95% CI: 0.51-1.08) [15]. Real-world cohort studies from Scandinavian registries comparing combination therapy to monotherapy demonstrate adjusted hazard ratios for MACE of 0.78 (95% CI: 0.71-0.87) and heart failure hospitalization of 0.72 (95% CI: 0.64-0.82), though residual confounding limits causal inference [24]. Mechanistic studies reveal complementary cardiovascular protection: GLP-1RAs reduce atherosclerotic plaque progression assessed by intravascular ultrasound (4-8% reduction in plaque volume) [41,42], while SGLT2i reduce left ventricular mass (5-10% reduction) and improve diastolic function (E/e' ratio improvements of 1-2 units) [55,64]. Biomarker studies show combination therapy reduces high-sensitivity C-reactive protein by 20-30%, N-terminal pro-B-type natriuretic peptide by 15-25%, and high-sensitivity troponin by 10-20%, suggesting anti-inflammatory and cardioprotective effects [65].

Renal Protection and Kidney Function Preservation

Renal outcomes demonstrate particular promise for combination therapy. The FLOW trial examining semaglutide in chronic kidney disease patients (published 2024) showed 24% reduction in kidney failure, death, or sustained eGFR decline, with benefits consistent across subgroups including those receiving SGLT2i [66]. Conversely, DAPA-CKD [67] and EMPA-KIDNEY [68] trials of SGLT2i showed preserved renal benefits in patients using GLP-1RAs. Meta-analyses of renal outcomes from cardiovascular trials demonstrate combination therapy associates with 30-40% lower risk of worsening nephropathy (composite of sustained eGFR decline ≥40%, end-stage kidney disease, or renal death) compared to standard care [76,77]. Mechanistically, SGLT2i provide immediate eGFR reductions of 3--5 mL/min/1.73m² ("eGFR dip") through hemodynamic effects [51,52], followed by stabilization and slower subsequent decline rates of 0.5-1.0 mL/min/1.73m² annually compared to 2-4 mL/min/1.73m² with standard therapy [67,68]. GLP-1RAs demonstrate smaller initial eGFR effects but preserve kidney function through anti-inflammatory mechanisms, reducing albuminuria by 15-30% [66]. Combination therapy produces complementary effects: immediate SGLT2i-mediated hemodynamic protection plus sustained GLP-1RA anti-inflammatory effects, potentially maximizing long-term kidney function preservation. Albuminuria reductions with combination therapy reach 30-50%, exceeding either monotherapy component [76].

Blood Pressure and Hemodynamic Effects

Both drug classes reduce blood pressure through distinct mechanisms producing additive effects [47,48]. SGLT2i-induced osmotic diuresis and natriuresis reduce systolic blood pressure by 3-5 mmHg and diastolic pressure by 1-2 mmHg, with greater effects in hypertensive patients (reductions up to 8 mmHg systolic) [43,44]. GLP-1RAs reduce blood pressure through weight loss-dependent mechanisms and direct vasodilatory effects, achieving 2-4 mmHg systolic reductions [40,62]. Combination therapy produces cumulative reductions of 5-8 mmHg systolic and 2-4 mmHg diastolic without increasing orthostatic hypotension risk [74,75]. Ambulatory blood pressure monitoring demonstrates consistent 24-hour blood pressure lowering without excessive nocturnal dipping [48]. Notably, these blood pressure reductions occur without reflex tachycardia, distinguishing these agents from traditional vasodilators [47]. The hemodynamic benefits contribute to cardiovascular risk reduction independent of glycemic control, as evidenced by cardiovascular benefits persisting in euglycemic heart failure trials (EMPEROR, DELIVER) where SGLT2i reduced heart failure outcomes despite minimal baseline diabetes prevalence [64,65].

SAFETY, TOLERABILITY, AND ADVERSE EVENTS

Gastrointestinal Adverse Events

Gastrointestinal side effects represent the most common tolerability concern, predominantly driven by GLP-1RA components [11,12]. Nausea occurs in 20-40% of patients initiating GLP-1RAs, though typically mild-to-moderate in severity and diminishing over 4-8 weeks [27,28]. Combination therapy does not appear to exacerbate GLP-1RA-associated nausea compared to GLP-1RA monotherapy, with SUSTAIN 9 reporting nausea in 21% of combination group versus 19% in GLP-1RA monotherapy historical controls [74]. Vomiting (5-15%), diarrhea (10-20%), and constipation (8-15%) occur at similar frequencies as GLP-1RA monotherapy [11,75]. Mitigation strategies include gradual dose titration over 8-16 weeks, administration with meals, temporary dietary modifications avoiding high-fat foods, and considering alternative GLP-1RA formulations with potentially better tolerability profiles [27]. Severe gastrointestinal adverse events leading to treatment discontinuation occur in 3-8% of patients, lower than earlier GLP-1RA trials reflecting improved dose titration protocols [28]. Importantly, gastrointestinal effects rarely persist beyond 12 weeks, and late-onset nausea should prompt evaluation for alternative etiologies including gastroparesis or pancreatitis [35,36].

Genitourinary Infections and Diabetic Ketoacidosis

SGLT2i-associated genitourinary infections constitute the primary safety concern specific to this drug class [13,14]. Genital mycotic infections (vulvovaginal candidiasis in women, balanitis in men) occur in 8-15% of patients, typically mild and responsive to topical antifungal therapy, with recurrence rates of 20-30% [43,44]. Risk factors include

baseline glycemia >10 mmol/L, history of candidiasis, and uncircumcised males [45]. Urinary tract infections occur in 5-10% of patients, without increased pyelonephritis risk [46]. Combination with GLP-1RAs does not significantly modify genitourinary infection risk, though improved glycemic control may marginally reduce infection rates [74,75]. Rare but serious SGLT2i-associated diabetic ketoacidosis (euglycemic DKA) occurs in <0.1% of T2DM patients, typically precipitated by physiologic stressors including surgery, severe illness, or very-low-carbohydrate diets [49,50]. Risk mitigation includes patient education regarding sick-day management, temporary SGLT2i discontinuation during acute illness or perioperative periods, and maintaining adequate carbohydrate intake [13,14]. Combination therapy does not appear to increase ketoacidosis risk beyond SGLT2i monotherapy, though vigilance remains warranted [76].

Hypoglycemia, Bone Health, and Other Safety Considerations

Hypoglycemia risk with combination therapy remains low when used without insulin or sulfonylureas, occurring in <5% of patients, predominantly non-severe events [31,32]. The glucose-dependent insulin secretion mechanism of GLP-1RAs combined with insulin-independent SGLT2i action creates inherent hypoglycemia protection [29,30]. Bone safety data show no increased fracture risk in meta-analyses [77], though initial concerns existed regarding SGLT2i-associated increased fracture rates in early canagliflozin trials; subsequent analyses suggest confounding by baseline fracture risk factors rather than causal effects [18]. Amputation risk associated with canagliflozin in CANVAS trial has not been observed with other SGLT2i, and combination therapy does not modify this risk [18]. Acute kidney injury occurs rarely (<1%), typically in context of volume depletion from intercurrent illness; temporary SGLT2i discontinuation during acute illness represents prudent risk mitigation [51,52]. Pancreatitis concerns with GLP-1RAs from early meta-analyses have not been confirmed in large cardiovascular outcome trials, with incidence rates of 0.1–0.3% comparable to background T2DM populations [15,16]. Medullary thyroid carcinoma risk remains theoretical based on rodent studies, with long-term pharmacovigilance data showing no increased human risk [11,12]; however, GLP-1RAs remain contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [27,28].

CLINICAL IMPLEMENTATION AND FUTURE DIRECTIONS

Patient Selection and Individualized Therapy

Optimal patient selection for combination therapy requires consideration of clinical phenotype, comorbidities, and treatment priorities [19,20]. Ideal candidates include patients with inadequate glycemic control (HbA1c >7.5–8.0%) on metformin monotherapy, baseline BMI >30 kg/m², established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors, and chronic kidney disease with eGFR 25–60 mL/min/1.73m² with albuminuria [21,22]. American Diabetes Association 2024 guidelines recommend early combination therapy in patients with HbA1c >9.0% or >1.5% above target to rapidly achieve glycemic control [8]. Cardiovascular phenotyping guides agent selection: patients with atherosclerotic cardiovascular disease may prioritize GLP-1RAs given stronger evidence for atherosclerotic event reduction [15,16], while those with heart failure or CKD prioritize SGLT2i given compelling heart failure hospitalization and renal benefits [17,18]. Economic considerations influence implementation; annual costs of combination therapy range $8,000–15,000 USD, substantially exceeding generic alternatives, necessitating cost-effectiveness justification through cardiovascular and renal event prevention [23,24]. Shared decision-making incorporating patient preferences regarding injection frequency, side effect tolerance, and weight loss priorities optimizes adherence [19,20]. Contraindications require assessment: GLP-1RAs are contraindicated in medullary thyroid carcinoma history [27,28], while SGLT2i require caution with recurrent genitourinary infections or eGFR <20 mL/min/1.73m² [43,44].

Real-World Effectiveness and Implementation Challenges

Real-world effectiveness data from observational registries demonstrate outcomes comparable to randomized trials, though with important caveats [24]. Scandinavian registry studies show combination therapy persistence rates of 60–75% at 12 months versus 50–65% for monotherapy, potentially reflecting higher treatment satisfaction [73]. However, gastrointestinal side effects cause discontinuation in 12-18% within 6 months, higher than trial discontinuation rates, likely reflecting less intensive clinical support in routine practice [27,28]. Healthcare disparities limit access: US insurance prior authorization requirements create barriers, with approval rates of 60–80% despite guideline recommendations, disproportionately affecting racial and ethnic minorities and low-income populations [19,20]. Polypharmacy burden concerns arise as combination therapy adds to existing metformin, antihypertensives, and statins, potentially impacting adherence [8]. Implementation science research identifies key facilitators: simplified treatment algorithms, clinical decision support tools embedded in electronic health records, and pharmacist-led medication optimization programs improve appropriate prescribing [19,20]. Quality improvement initiatives demonstrate that systematic protocols incorporating cardiovascular risk assessment increase combination therapy utilization from 15% to 40% in eligible patients over 18-month implementation periods [21,22].

Emerging Agents and Next-Generation Therapies

Pharmaceutical development focuses on optimizing combination therapy through novel formulations and mechanisms [82,83]. Dual agonists including tirzepatide (GLP-1/GIP receptor co-agonist) demonstrate superior efficacy to selective GLP-1RAs, with SURPASS trials showing HbA1c reductions of 1.9-2.4% and weight loss of 7--12 kg, though head-to-head combination comparisons with GLP-1RA plus SGLT2i remain absent [84]. Triple agonists (GLP-1/GIP/glucagon receptor) in phase 2 trials show even greater weight reductions (15-20% body weight) with preserved glycemic efficacy, though clinical development for T2DM specifically continues [85,86]. Fixed-dose combinations containing GLP-1RA and SGLT2i within single formulation could improve adherence and simplify regimens, though pharmaceutical development faces challenges regarding compatible pharmacokinetics and stability [58]. Beyond diabetes, expansion of indications includes heart failure with preserved ejection fraction (SGLT2i FDA-approved based on DELIVER/EMPEROR-Preserved trials) [64,65] and chronic kidney disease regardless of diabetes status (based on DAPA-CKD/EMPA-KIDNEY) [67,68]. Ongoing trials including SOUL (semaglutide cardiovascular outcomes) [87] and FLOW (semaglutide renal outcomes) [66] will further define optimal combination strategies. Personalized medicine approaches using genetic, metabolic, and biomarker profiling to predict treatment response remain investigational but represent future directions for precision diabetes management [88,89].

Research Gaps and Unmet Needs

Critical knowledge gaps persist despite robust clinical trial evidence [23,24]. Long-term safety beyond 3--5 years remains incompletely characterized, particularly regarding potential cumulative effects on bone metabolism, pancreatic function, and thyroid health [77]. Optimal treatment sequencing (simultaneous initiation versus sequential addition) lacks prospective comparison, with current practice varying widely across providers [19,20]. Pediatric and adolescent T2DM treatment evidence remains limited, though rising youth diabetes prevalence necessitates age-specific efficacy and safety data [4,5]. Pregnancy safety data are insufficient, with current recommendations advising discontinuation during pregnancy planning [27,28]. Mechanistic understanding of cardiovascular and renal benefits remains incomplete; whether benefits result predominantly from metabolic improvements or direct organ-protective effects requires further elucidation through biomarker substudies and mechanistic trials [65,76]. Cost-effectiveness analyses show inconsistent results across healthcare systems, ranging from cost-effective to not cost-effective depending on willingness-to-pay thresholds, event rates, and time horizons, necessitating health economic research incorporating broader societal perspectives [23,24]. Importantly, virtually all major trials enrolled predominantly white populations, limiting generalizability to racial and ethnic minorities who bear disproportionate diabetes burden [19,20]. Health equity research examining implementation barriers, treatment response variability, and strategies to reduce disparities represents critical priority [90].

CONCLUSION

Combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors represents an evidence-based advancement in type 2 diabetes management, offering synergistic benefits across multiple therapeutic domains. The biochemical rationale is compelling: complementary mechanisms address distinct pathophysiologic defects through incretin-mediated insulin enhancement, glucagon suppression, appetite reduction, and insulin-independent renal glucose excretion. Clinical evidence demonstrates superior glycemic control with HbA1c reductions of 1.0--1.5%, meaningful weight loss of 5--8% body weight, blood pressure reductions of 5--8 mmHg systolic, and convergent cardiovascular and renal protection exceeding either monotherapy component. Safety profiles remain acceptable, with predominantly self-limited gastrointestinal and genitourinary adverse events manageable through patient education and dose titration strategies. The evidence base supporting combination therapy has matured substantially, transitioning from mechanistic rationale to clinical validation through randomized trials and real-world effectiveness studies, though dedicated cardiovascular outcome trials specifically examining combination therapy remain absent. Current diabetes management guidelines appropriately position GLP-1RAs and SGLT2i as preferred second- and third-line agents after metformin, with combination therapy indicated for patients requiring intensive glucose lowering or possessing cardiovascular and renal comorbidities. Remaining challenges include cost barriers limiting access, healthcare disparities in utilization, long-term safety uncertainties, and knowledge gaps regarding optimal patient selection. The transformative aspect of these therapies extends beyond glucose lowering to comprehensive cardio-metabolic-renal risk reduction, fundamentally redefining diabetes management objectives toward holistic organ protection. Clinical practice should prioritize early implementation of GLP-1 receptor agonist and SGLT2 inhibitor combination therapy in type 2 diabetes patients with inadequate glycemic control on metformin monotherapy, established cardiovascular disease, heart failure, or chronic kidney disease, while healthcare systems must address cost and access barriers to ensure equitable availability of this evidence-based therapeutic strategy.

REFERENCES

1. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OP-C, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat Prod Commun. 2025;20(3). doi:10.1177/1934578X251323393
2. Krishnamoorthy R, Gatasheh MK, Subbarayan S, Vijayalakshmi P, Uti DE. Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Nat Prod Commun. 2024;19(12). doi:10.1177/1934578X241299279
3. Alum EU. Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 2025;22:44. doi:10.1186/s12982-025-00445-5
4. Ikpozu EN, Offor CE, Igwenyi, I.O, Ibiam, U.A., Obaroh, I.O. et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251334726
5. Mitaki, N.B., Fasogbon, I.V., Ojiakor, O.V., Makena, W., Ikuomola, E. O., Dangana, R.S., et al. (2025). A systematic review of plant-based therapy for the management of diabetes mellitus in the East Africa community. Phytomedicine Plus, 5(1): 100717. https://doi.org/10.1016/j.phyplu.2024.100717
6. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and
7. United States Renal Data System. 2023 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2023. Available at: https://adr.usrds.org
8. ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. doi:10.2337/dc24-S009
9. Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426. doi:10.2337/dc17-1144
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
11. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
12. Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217-4227. doi:10.1172/JCI97233
13. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11-26. doi:10.1038/nrneph.2016.170
14. Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317-336. doi:10.1038/s41581-020-0256-y
15. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
16. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
17. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
18. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
19. Edelman SV, Polonsky WH. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care. 2017;40(11):1425-1432. doi:10.2337/dc16-1974
20. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624. doi:10.1056/NEJMsa1213829
21. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and GLP-1 Receptor Agonists: Combination Therapy for Type 2 Diabetes. Diabetes Care. 2015;38(6):1115-1122. doi:10.2337/dc14-2477
22. Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther. 2019;10(5):1771-1792. doi:10.1007/s13300-019-00686-z
23. Castellana M, Cignarelli A, Brescia F, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci Rep. 2019;9(1):19351. doi:10.1038/s41598-019-55524-w
24. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. doi:10.1016/S2213-8587(19)30249-9
25. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010

26. Holst JJ, Rosenkilde MM. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. J Clin Endocrinol Metab. 2020;105(8):e2710-e2716. doi:10.1210/clinem/dgaa327
27. Meier JJ. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. Front Endocrinol (Lausanne). 2021;12:645617. doi:10.3389/fendo.2021.645617
28. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017;318(15):1460-1470. doi:10.1001/jama.2017.14752
29. Zhao X, Wang M, Wen Z, et al. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021;12:721135. doi:10.3389/fendo.2021.721135
30. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. doi:10.1016/j.cmet.2013.04.008
31. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
32. Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res. 2011;317(9):1239-1245. doi:10.1016/j.yexcr.2011.01.010
33. Holst JJ, Albrechtsen NJW, Gabe MBN, Rosenkilde MM. Oxyntomodulin: Actions and role in diabetes. Peptides. 2018;100:48-53. doi:10.1016/j.peptides.2017.09.018
34. Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother. 2017;18(6):555-571. doi:10.1080/14656566.2017.1282463
35. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21. doi:10.1111/dom.13129
36. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi:10.3389/fendo.2021.645563
37. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi:10.1172/jci.insight.133429
38. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488. doi:10.1172/JCI75276
39. Ussher JR, Drucker DJ. Cardiovascular Actions of Incretin-Based Therapies. Circ Res. 2014;114(11):1788-1803. doi:10.1161/CIRCRESAHA.114.301958
40. Helmstädter J, Frenis K, Filippou K, et al. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2020;40(1):145-158. doi:10.1161/ATVBAHA.119.313736
41. Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844-857. doi:10.1016/j.jacbts.2018.09.004
42. Nikolic D, Giglio RV, Rizvi AA, et al. Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients With Type 2 Diabetes: A Novel Anti-Atherogenic Effect. Diabetes Ther. 2021;12(1):261-274. doi:10.1007/s13300-020-00962-3
43. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
44. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744
45. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508. doi:10.1172/JCI72227
46. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262-274. doi:10.7326/0003-4819-159-4-201308200-00007
47. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853-862. doi:10.1111/dom.12127
48. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081
49. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1730-1735. doi:10.2337/dc15-0355
50. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-517. doi:10.1038/nm.3828

51. Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26-39. doi:10.1016/j.kint.2017.12.027
52. van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202-212. doi:10.1016/j.kint.2019.09.013
53. Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts.2020.02.004
54. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119-132. doi:10.1007/s10557-017-6725-2
55. Verma S, Mazer CD, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693-1702. doi:10.1161/CIRCULATIONAHA.119.042375
56. Packer M. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. Circ Heart Fail. 2020;13(9):e007197. doi:10.1161/CIRCHEARTFAILURE.120.007197
57. Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021;9(8):578-589. doi:10.1016/j.jchf.2021.04.014
58. Blonde L, Belousova L, Fainberg U, et al. Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a randomized, placebo-controlled trial. Diabetes Obes Metab. 2020;22(6):929-937. doi:10.1111/dom.13978
59. Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hissa M, Derwahl KM. Safety and tolerability of linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥65 years. Diabetes Obes Metab. 2014;16(11):1083-1093. doi:10.1111/dom.12306
60. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-1016. doi:10.1016/S2213-8587(16)30267-4
61. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and Safety of Canagliflozin When Used in Conjunction With Incretin-Mimetic Therapy in Patients With Type 2 Diabetes. Diabetes Obes Metab. 2016;18(1):82-91. doi:10.1111/dom.12589
62. Bizino MB, Jazet IM, Westenberg JJM, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55. doi:10.1186/s12933-019-0857-6
63. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662. doi:10.1016/S2213-8587(21)00203-5
64. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038
65. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286
66. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347
67. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
68. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233
69. Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19(9):1276-1288. doi:10.1111/dom.12954
70. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular

and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022-2031. doi:10.1161/CIRCULATIONAHA.118.038868
71. Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Cholelithiasis in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;161:108087. doi:10.1016/j.diabres.2020.108087
72. Jabbour S, Guja C, Hardy E, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care. 2018;41(10):2136-2146. doi:10.2337/dc18-0680
73. Guja C, Frías JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes Obes Metab. 2018;20(7):1602-1614. doi:10.1111/dom.13266
74. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356-367. doi:10.1016/S2213-8587(19)30066-X
75. Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(5):370-381. doi:10.1016/S2213-8587(18)30023-8
76. Mantsiou A, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2021;23(8):1818-1830. doi:10.1111/dom.14400
77. Patoulias D, Papadopoulos C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A. Meta-Analysis Assessing the Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass and Fat Mass in Patients with Type 2 Diabetes Mellitus. Am J Cardiol. 2021;154:128-130. doi:10.1016/j.amjcard.2021.05.041
78. Harreiter J, Roden M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023). Wien Klin Wochenschr. 2023;135(Suppl 1):7-17. doi:10.1007/s00508-022-02122-y
79. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi:10.1038/nrdp.2015.19
80. Halimi S, Raccah D, Schweizer A, Dejager S, Yannovits N, Maleki K. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin. 2010;26(6):1647-1656. doi:10.1185/03007995.2010.480971
81. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4
82. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
83. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
84. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
85. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6
86. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
87. Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. doi:10.1056/NEJMoa1901118
88. Neeland IJ, Marso SP, Ayers CR, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595-605. doi:10.1016/S2213-8587(21)00179-0
89. Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65(5):1190-1195. doi:10.1037/db15-1356
90. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social Determinants of Health and Diabetes: A Scientific Review. Diabetes Care. 2020;44(1):258-279. doi:10.2337/dci20-0053

CITE AS: Muhindo Edgar (2026). GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Type 2 Diabetes Management. IAA Journal of Biological Sciences 14(1):45-54. https://doi.org/10.59298/IAAJB/2026/1414574